Gina Castro Nicita
About Gina Castro Nicita
Gina Castro Nicita serves as the Senior Product Management Director for GTM and Product Strategy at Carelon, where she has worked since 2021. With extensive experience in healthcare management and a strong focus on public health, she oversees a significant portfolio and has a background in digital healthcare innovation.
Work at Carelon
Gina Castro Nicita currently serves as the Senior Product Management Director for GTM and Product Strategy at Carelon, a position she has held since 2021. In this role, she oversees a portfolio valued at $30 million, managing over 15 projects. Prior to this, she worked as the Senior Product Management Director for Clinical Exploration and Innovation at Carelon from 2019 to 2021. During her tenure, she launched Anthem's first HIPAA compliant, agnostic telehealth platform, demonstrating her expertise in digital healthcare innovation.
Education and Expertise
Gina Castro Nicita holds a Master of Science degree in Computer Information Systems from Regis University. She is also pursuing a Master of Healthcare Administration & Interprofessional Leadership (MS-HAIL) at the University of California, San Francisco, which she has been studying since 2017. Her educational background supports her extensive experience in healthcare management and product strategy.
Background
Before joining Carelon, Gina held various significant roles in the California Department of Public Health. From 2015 to 2019, she was the Senior Manager for Health Care Programs in the Genetic Disease Screening Program. Earlier, she served as the Biobank Manager for the same department from 2012 to 2015, managing a biobank facility that was the largest of its kind in California. Her career also includes a position as Senior Project Manager at Kaiser Permanente from 2006 to 2009.
Achievements
Gina Castro Nicita has directed substantial financial management efforts, including overseeing a $200 billion system investment initiative. She has been instrumental in delivering genetic screening products for 500,000 newborns annually, addressing over 80 congenital disorders. Her leadership in managing large-scale initiatives is evident through her oversight of a $30 million portfolio at Carelon.